Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

On the Road in Nevada with Avidian Gold CEO Steve Roebuck

(Click to play.) Avidian Gold Corp. ( TSX-V: AVG , Forum ) is a Canada-based mineral exploration company. Principally, it is engaged in the business of acquiring and exploring gold projects. The company holds right to explore several properties comprising of Gold...
Featured Submission | April 21, 2022 |

Surging Retail Sales, Cautious Powell, and Gold

Retail sales came in really strong in May, which could strengthen risk appetite, but the dovish Fed should support gold. However, the sales were still 6 percent lower than a year ago, which means that the coronavirus crisis has not ended yet. But such reports may, neve...
Arkadiusz Sieron | June 18, 2020 |

Biotech's Mosquito Test 'Gains Market Acceptance

This West Nile virus test and others including cancer diagnostic tests in the Utah company's pipeline are discussed in an H.C. Wainwright & Co. report. In a July 31 research note, H.C. Wainwright & Co. analyst Yi Chen reported the market has increasingly adopte...
Streetwise Reports | August 6, 2019 |

Biotech's DMD Therapeutic 'Solidifies the Ground for Potential Pivotal Design'

The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report. In an Aug. 8 research note, analyst Joseph Pantginis reviewed Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Q2/19 financials and reported t...
Streetwise Reports | August 14, 2019 |

Canadian Solar Shares Shine on Sunny Quarterly Earnings

Canadian Solar, which operates a portfolio of utility-scale solar operated power plants, reported higher Q2 earnings. This morning one of the world's largest solar power companies, Canadian Solar Inc. (CSIQ:NASDAQ) , announced financial results for the ...
Streetwise Reports | August 20, 2019 |

After Biotech Dives Deeper Into Melanoma Data, It 'Continues to Impress'

Details from this clinical program are discussed, along with Q2/19 earnings and the next stock catalyst, in an H.C. Wainwright & Co. report. In an Aug. 23 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported the highlights from Targovax ASA's (TRVX:...
Streetwise Reports | August 28, 2019 |

FDA Approves First-of-Its-Kind, Adult Pneumonia Antibiotic; September Launch Planned

The drug's features and its developer's commercial plans are discussed in an H.C. Wainwright & Co. report. In an Aug. 20 research note, analyst Ed Arce reported that H.C. Wainwright & Co. raised its target price on Nabriva Therapeutics Plc (NBRV:NASDAQ) to $8 per sh...
Streetwise Reports | August 28, 2019 |

NCI Chooses Veterinary Biopharma as Select Manufacturing Contractor

The contract's meaning, terms and benefits and the California firm's near-term catalysts are discussed in an H.C. Wainwright & Co. report. In a Sept. 12 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Kindred Biosciences Inc. (KIN:NA...
Streetwise Reports | September 19, 2019 |

Coverage Initiated on U.S.-Based Precision Therapy Developer

The key reasons this story is compelling are given in an H.C. Wainwright & Co. report. In an Oct. 3 research note, analyst Andrew Fein reported that H.C. Wainwright & Co. initiated coverage on Blueprint Medicines Corp. (BPMC:NASDAQ) with a Buy rating and a $100 per ...
Streetwise Reports | October 9, 2019 |

Biotech's Topline Breast Cancer Data Impresses

Biotech's Topline Phase 3 HER2-Positive Breast Cancer Data 'Impresses' The results and commercial potential of the therapeutic are discussed in an H.C. Wainwright & Co. report. In an Oct. 22 research note, H.C. Wainwright & Co. analyst Andrew Fein reported that t...
Streetwise Reports | October 24, 2019 |
1 2 3 4